

We put science to work.™

OPERATED BY SAVANNAH RIVER NUCLEAR SOLUTIONS

SRNL Mo-99 Technical Support for SHINE™

Discussion on Tritiated Waste Disposition Pathways for Commercial Entities

Nancy Halverson

SRNL

Presentation for Tritium Focus Group Meeting Los Alamos, NM


November 3, 2015

SRNL-L2100-2015-00098



- "Molybdenum-99 is the parent isotope of technetium-99m (^{99m}Tc)
 - ⁹⁹Mo is loaded into ^{99m}Tc generator and is produced by ⁹⁹Mo decay
 - ^{99m}Tc is extracted (by radiopharmacy staff) for use in patients
- ^{99m}Tc is a light-emitting element used to diagnose and stage a multitude of diseases, including cancer and heart disease
- ^{99m}Tc is administered to some 55,000 Americans every day
- ^{99m}Tc is used in over 80% of nuclear diagnostic procedures worldwide "The heart of modern nuclear medicine."
- North America uses about 50% of the world's Mo-99 supply

- Myocardial perfusion studies are typically done to diagnose and stage heart disease.
- Bone scans are typically performed for cancer staging.




Isotope Production," November, 2009

• NRU Reactor at Chalk River, Ontario, Canada is scheduled for shutdown in 2016; produces about 40% of the world's supply of Mo-99.




- 85-95% of the world's Mo-99 is produced via the use of highly enriched uranium (HEU) targets.
- Mo-99 Program mission is to convert Mo-99 production to use Low Enriched Uranium (LEU) a non-proliferation initiative.
- NNSA Mo-99 Programs have formed cooperative agreements with several companies to support the continued development and commercialization of the medical radioisotope molybdenum-99 (Mo-99) production without the use of highly enriched uranium (HEU).

 SHINE Medical Technologies will produce ⁹⁹Mo using a deuterium-tritium accelerator to produce neutrons which irradiate the Low Enriched Uranium (LEU) solution




• GOAL: Start Production in 2018!!!!! (Slip from target 2016 production date is based on funding profile; contingent on NRC authorization)



UPDATE October 2015 – The Nuclear Regulatory Commission (NRC). The NRC staff have completed their environmental and safety reviews of the SHINE facility and have recommended that SHINE be issued a Construction Permit. SHINE now enters the final stage of the permitting process, which includes a hearing with the NRC Commissioners in Dec 2015.

SHINE Production Facility (2014 Mo-99 Topical Meeting)


- Accelerator uses tritium-deuterium gases to produce neutrons
- Tritium (deuterium) supplied and received must be processed to achieve remove impurities and condition waste gases for discharge
 - TCAP is the technology that connected SHINE to SRNL
 - TCAP is very robust and versatile, but is only one component of the tritium fuel cycle that is needed to operate an accelerator (or any other tritium/energy producing process)



Savannah River National Laboratory

- Three types of tritiated waste (solid, liquid, and gas) will be generated from operations of the TPS process, TPS glovebox, the Accelerator Tritium Interface System (ATIS), and the ATIS gloveboxes.
- Functions and requirements were developed for the tritiated waste and associated tritiated waste storage areas. (Ref: TPS Tritiated Waste Interface Control Document)
- The Tritiated Waste Assessment will identify commercial pathways to dispose of tritiated waste for SHINE and document in a releasable report.

Tritium Purification System (TPS) Interfaces for Tritiated Wastes





Summary

• Goal

- Evaluate disposition pathways for tritiated waste for commercial entities such as SHINE
- Tritiated Waste Disposition Pathways (government and private)
 - National Laboratory
 - Commercial Entities
- NWC Site Contact Information for Tritiated Wastes?
 - LANL
 - PPPL
 - PNNL
 - Others?
- Nancy Halverson, SRNL

Nancy.halverson@srnl.doe.gov

